Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr.

On November 2, 2025, Vor Biopharma Inc. amended the employment agreement with its Chief Development Officer, Dr. Qing Zuraw, to include additional severance benefits in case of termination without ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $47.68 / share. This is an increase of ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms100% of patients on telitacicept ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...

The stock options have a ten-year term, and the exercise price is $30.22 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The ...

VORs (Very High Frequency Omni-Directional Range) are ground-based radio navigation aids that historically guided aircraft by transmitting signals allowing pilots to determine their bearing from the ...